Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-106 (ES102) in Greater China

May 01 , 2018 10:00

Shanghai and San Diego, May 1st 2018. Elpiscience Biopharmaceutical Ltd (Elpiscience) has entered into a licensing agreement with Inhibrx, Inc., pursuant to which Elpiscience was granted an exclusive right to develop and commercialize INBRX-106 (ES102) in mainland China, Hongkong, Macau and Taiwan.

ES102 is a hexavalent OX40 agonistic antibody with a unique “first-in-class” design. The special design of ES102 allows for efficient OX40 agonism even in the absence of exogenous cross-linking. ES102 induces much strong immune activation compared to tetrameric or conventional bivalent OX40 antibodies.

About ES102

ES102 is a hexavalent OX40 agonistic antibody with best-in-class potential. ES102 has shown impressive anti-tumor efficacy as monotherapy in pre-clinical models compared to conventional bivalent antibodies and has the potential to translate clinically. OX40, also known as CD134, is a member of the tumor necrosis factor (TNF) receptor family and is an important co-stimulator of T cell responses. Typically for TNF receptor family members, 3 molecules of OX40 bind to the trimeric OX40 ligand protein, activating downstream NF-κB, PI3K, and AKT pathways, which ultimately leads to increased cytokine production and is associated with enhanced T-cell expansion, differentiation, and the generation of long-lived memory T-cells.

About Elpiscience

Elpiscience is a top-tier investor backed biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience’s innovations cover a wide range of immunology targets with a focus on innate immunity and tumor microenvironment.

About Inhibrx

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.